LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, has expanded the second cohort from its Phase
II clinical trial of its lead drug candidate PB272 (neratinib) as a
single agent in patients with solid tumors who have an activating HER2
mutation (basket trial). The cohort that has been expanded is the cohort
that includes patients with metastatic non-small cell lung cancer and
whose tumors have a HER2 mutationmore...